Every 10-Q that Rocket Pharmaceuticals, Inc. (RCKT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RCKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCKT filings page.
Rocket Pharmaceuticals, Inc. reported a sharp swing to profitability for the quarter ended June 30, 2026, driven by monetizing its Rare Pediatric Disease Priority Review Voucher. Net income was $123.2 million versus a net loss of $68.9 million a year earlier, primarily reflecting a $178.2 million gain on the PRV sale for $180 million.
Operating performance remained loss-making but more efficient. For the quarter, research and development expense fell to $29.5 million from $42.7 million, and general and administrative expense declined to $17.4 million from $25.0 million, with no new restructuring charges. Six‑month net income was $75.6 million versus a $130.3 million loss in 2025.
Liquidity improved significantly: cash, cash equivalents and investments totaled $283.7 million at June 30, 2026, up from $188.9 million at year‑end 2025, supporting management’s view that existing resources can fund operations into the second quarter of 2028. KRESLADI™ received FDA accelerated approval in March 2026, but the company has not yet generated product revenue and continues to invest in launch activities and its cardiovascular genetic medicines pipeline. The company also disclosed ongoing shareholder and derivative litigation related to prior Danon disease trial communications.
Rocket Pharmaceuticals reported another quarterly loss as it transitions to commercial stage. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $47.6 million versus $61.3 million a year earlier, as both research and development and general and administrative expenses declined.
Cash, cash equivalents and investments totaled $144.4 million as of March 31, 2026. In March, the FDA granted accelerated approval for KRESLADI™ for severe LAD‑I, and in April the company signed a definitive agreement to sell the related Priority Review Voucher for $180 million, which management expects will provide non‑dilutive funding to support its cardiovascular gene therapy pipeline and extend its operating runway by at least twelve months. Rocket also continues to face class action and derivative litigation tied to disclosures about its Danon disease program.
Rocket Pharmaceuticals (RCKT) filed its Q3 2025 10‑Q, reporting continued investment in late-stage gene therapies without revenue. Net loss was $50.3 million for the quarter and $180.6 million for the nine months ended September 30, 2025. Operating expenses declined year over year as R&D fell to $34.1 million from $42.3 million and G&A to $18.4 million from $27.1 million, reflecting portfolio reprioritization.
Cash, cash equivalents and investments totaled $222.8 million as of September 30, 2025, and the company expects this to fund operations into the second quarter of 2027. Stockholders’ equity was $313.7 million. Rocket implemented a strategic reorganization in July 2025, reducing its workforce by ~30% and recording $3.3 million in restructuring charges year to date.
In clinical updates, the FDA lifted the clinical hold on the RP‑A501 Phase 2 trial on August 20, 2025 after the company addressed issues outlined in the hold. A prior intellectual property dispute with Lexeo was settled with no material financial impact.